Mirasol Evaluation of Reduction in Infections Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

2,000

Participants

Timeline

Start Date

November 13, 2019

Primary Completion Date

September 29, 2025

Study Completion Date

September 29, 2025

Conditions
Transfusion-Transmitted Infectious Disease
Interventions
BIOLOGICAL

Mirasol-treated Fresh Whole Blood

Standard issue FWB, which gave negative serological assay results for HIV, HBV, HCV, and syphilis will subsequently be treated with Mirasol PRT, then stored at 1 - 6 degrees Celsius and transfused within 21 days of collection.

BIOLOGICAL

Standard Fresh Whole Blood

Fresh whole blood that gave negative serological assay results for HIV, HBV, HCV, and syphilis will be stored at 1 - 6 degrees Celsius and transfused within 21 days of collection.

Trial Locations (1)

Unknown

Mulago Hospital Complex, Kampala

All Listed Sponsors
collaborator

Terumo BCT

INDUSTRY

collaborator

MU-JHU CARE

OTHER

collaborator

United States Department of Defense

FED

lead

Johns Hopkins University

OTHER

NCT03737669 - Mirasol Evaluation of Reduction in Infections Trial | Biotech Hunter | Biotech Hunter